Результаты поиска

Oncology distress screening within predominately Black Veterans: Outcomes on supportive care utilization, hospitalizations, and mortality.

BackgroundWe evaluated whether patients' initial screening symptoms were related to subsequent utilization of supportive care services and hospitalizations, and whether patient-level demographics, symptoms, hospitalizations, and supportive care service utilization were associated with mortality in primarily low-income, older, Black Veterans with cancer.MethodsThis quality improvement project created collaborative clinics to conduct cancer distress screenings and refer to supportive care services at an urban, VA medical center. All patients completed a distress screen with follow-up screening e

Совпадение в полном тексте источника
… Veterans completed paper‐form screening as they awaited being seen by their oncologists, and returned the form to the triage nurse, who then shared them with the patients' treating oncologist. … Oncologist . 2017 ; 22 : 995 ‐ 1001 . 28476945 10.1634/theoncologist.2016-0500 PMC5553963 27 Martin JL , Azizoddin DR , Rynar LZ , et al. Comprehensive and equitable care for vulnerable veterans with integrated palliative, psychology, and oncology care . …

Psychological Distress Among Cancer Patients During COVID-19 Pandemic in the World: A Systematic Review.

Aim: Patients with malignancies, experience high rates of psychological distress. Fear of Corona-infection combined with the interruptions in some treatment programs might affect the psychological health of cancer patients. This review study was conducted to investigate the psychological distress among cancer patients during COVID-19 pandemic to offer system-adapted individual solutions. Materials and methods: To identify the psychological distress of cancer patients, a comprehensive search was carried out in PubMed, Web of Science, and Scopus. English language and original articles were inclu

INPART - a psycho-oncological intervention for partners of patients with haemato-oncological disease - study protocol.

BackgroundSuffering from cancer confronts both the patient and their partner with a number of psychosocial challenges in various aspects of their life. These challenges may differentially impact on quality of life, coping ability and compliance to treatment. This especially holds true for haemato-oncological diseases. To date, psychological interventions have predominantly been developed for oncological patients however specific interventions for partners of haemato-oncological patients are rare. In this study we aim to conduct a psycho-oncological group-intervention for partners of patients w

Совпадение в полном тексте источника
… Subjects of the control group will be treated as usual (optional unspecific contacts with a psycho-oncologist). At all assessments partners and patients are asked to fill out the questionnaires. The study protocol has been approved by the ethical review boards of each of the three centres. … Control group The control group receives one structured psycho-oncological consultation (Control condition/Care as usual), which is regularly conducted by trained psycho-oncologists The duration of the consultation is approximately 30 min. …

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazone linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload. In clinical studies to date,

Recent advances in precision oncology research.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… This will enable oncologists to rapidly and accurately identify effective drugs to treat cancer based on a patient’s unique proteogenomic (i.e., combination of gene and protein expression) profile. … Data obtained by WGS and RNA-seq were analyzed by oncologists and bioinformatics experts or by IBM Watson Genomic Analytics (WGA). The WGA is an automated system that prioritizes somatic variants and identifies drug candidates. …

Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.

OBJECTIVES: Until recently, no prospective epidemiologic survey of lymphoma and multiple myeloma (L/MM) in European cancer patients had been conducted; furthermore, data on prevalence, incidence, and treatment patterns of L/MM were limited or unavailable. Here we define anemia prevalence, incidence, and treatment patterns, and identify anemia risk factors in European L/MM patients. METHODS: Data for a subgroup of 2360 L/MM patients in the European Cancer Anaemia Survey (ECAS) were analyzed; variables included age, gender, tumor type/stage, cancer and anemia treatment, WHO performance status,

Challenges in Treating Cancer Patients With Unstable Psychiatric Disorder.

In this review, we first present a case of chronic myeloid leukemia with acute psychosis, and then we will discuss the incidence of cancer in patients with psychotic disorders, the manifestations of new-onset psychosis, and the prevalence of preexisting psychosis in cancer patients, coupled with their impact on the treatment, diagnosis, and prognosis of cancer. This was a case that presented with acute psychosis and was found to have an elevated white blood cell count upon admission to an inpatient psychiatric unit. He was diagnosed with chronic myeloid leukemia and successfully managed with i

Совпадение в полном тексте источника
… Oncologists may be hesitant in enrolling these patients in clinical trials or recommend intensive treatment due to their noncompliance. Cancer diagnosis and treatment are stressors that may cause new-onset depression or anxiety and exacerbate pre-existing mental illnesses. … Oncologist. 2019;24(7):901–910. doi: 10.1634/theoncologist.2018-0488. Associated Data Data Availability Statement Data are available within the article and in a public repository that issues datasets with DOIs. …

Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ), which was first reported as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a rare but severe soft and hard tissue disease induced by several types of medications. There has been a deluge of information about MRONJ, such as epidemiology, risk factors, clinical recommendations for dental treatment to prevent it, and treatment strategies in medication-prescribed users. The aim of this study was to comprehensively review recent articles and provide the current scientific information about MRONJ, e

Совпадение в полном тексте источника
… Communication between the oncologists and/or physicians and dentists is strongly encouraged. … Oncologist. 2011;16(1):121–132. doi: 10.1634/theoncologist.2010-0183. 9. …

Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.

Cancer-associated venous thromboembolism (CA-VTE) is a significant complication in oncology, contributing to morbidity, mortality, and increased healthcare utilization. Due to multiple patient- and disease-related factors, patients with cancer are at a markedly elevated risk for VTE, particularly within the first 6 months of diagnosis. The aim of this review is to provide an overview of current challenges and unmet needs in CA-VTE prediction, prevention and management. While the Khorana score remains the most widely used risk stratification tool, its limited sensitivity has prompted the develo

Совпадение в полном тексте источника
… Despite guideline inclusion, fondaparinux remains underrecognized among oncologists, reflecting its lower grade of recommendation compared with LMWH (1A) and direct oral anticoagulants (1A), limited cancer-specific trial data, and absence from simplified treatment algorithms. … Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study Oncologist 2017 22 601 608 10.1634/theoncologist.2016-0246 28424324 PMC5423517 65. Godinho J. Casa-Nova M. Moreira-Pinto J. Simoes P. Paralta Branco F. Leal-Costa L. Faria A. Lopes F. Teixeira J.A. …

Clinical Posters From JADPRO Live 2023.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Current challenges in cancer care include shortages of oncologists, nurses, and other allied staff, increase administrative burden, accreditation, and regulatory requirements, and more. … Methods: At UM/SCCC, APPs practice collaboratively with oncologists and the State of Florida scope of practice is restricted. As a result, independent billing opportunities are limited. …

Biosimilars in Oncology: Latest Trends and Regulatory Status.

Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment and supportive care. Biosimilar medications (or biosimilars) are very similar to the reference biologic drugs, although they are not identical. As patent protection for some of the most extensively used biologics begins to expire, biosimilars have the potential to enhance access and provide lower-cost options for cancer treatment. Initially, r

Совпадение в полном тексте источника
… In one study, Cook et al. reported that only 26% of oncologists and 21% of practitioners are aware of the idea of biosimilars [ 13 ]. … Many oncologists are not aware of the advantages of using biosimilars over biologics, due to lack of safety data available in the market. …

Cardiovascular risk in cancer patients: initial experience from a cardio-oncology clinic in Mexico.

OBJECTIVE: To describe the cardiovascular risk from Mexican patients scheduled to initiate cancer treatment and to compare the risk between oncological and hematological malignancies. METHODS: We enrolled patients referred for echocardiography before initiating cancer therapies. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) was evaluated. To estimate the risk for developing cancer therapy-related cardiovascular toxicity (CTR-CVT) we used the Heart Failure Association-International Cardio-Oncology Society risk score (HFA-ICOS). RESULTS: 106 patients were studi

Совпадение в полном тексте источника
… Accordingly, patients identified in the high and very high-risk categories require a cardiology referral (preferentially a cardio-oncologist), while patients in the low-risk category should proceed to anticancer therapy without delay 10 . … A multidisciplinary team discussion between oncologists and cardiologists to balance the risk/benefit of cardiotoxic anticancer treatment before starting treatment in high and very-high-risk patients is recommended. …

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations.

Randomized controlled trials (RCT) are the driver of therapeutic innovations. However, it has been frequently shown that less than 5% of adult cancer patients enroll in clinical trials, although 70% of patients are considered as being willing to participate. Barriers to trial participation have been extensively studied. Although there is evidence that trial participation correlates with improved survival and reduced mortality, the rate of participation has not changed substantially. We provide retrospective data from a single-center analysis of 411 patients with multiple myeloma (MM) who were

Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).

Improvements in chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) treatment options have increased the 5-year survival rates for patients with these hematologic malignancies. In addition to cancer management, these patients may need help to manage multiple chronic conditions (MCC). The overall objective of this study is to examine the impact and implementation of a model that coordinates care between oncology and primary care pharmacists for people taking an oral anti-cancer agent (OAAs) and medications for comorbid chronic conditions. This is a mult

Совпадение в полном тексте источника
… oncologists or oncology office personnel? primary care physicians? … The role of primary care physicians in advance cancer care: perspectives of older patients and their oncologists. J Am Geriatr Soc. 2009;57(Supp 2):S265–S268. doi: 10.1111/j.1532-5415.2009.02508.x. 25. Watanabe S.M., Nekolaichuk C.L., Beaumont C. …

Characteristics of Traditional Chinese Medicine Use in Pediatric Cancer Patients: A Nationwide, Retrospective, Taiwanese-Registry, Population-Based Study.

BackgroundLarge-scale surveys of complementary traditional Chinese medicine (TCM) use in pediatric cancer patients are lacking. The aim of our study was to investigate the use of TCM in pediatric cancer patients.MethodsWe analyzed cancer patients younger than 18 years (n = 12 965) who were registered in the National Health Insurance Research Database in Taiwan between 2001 and 2011. Patients were categorized into TCM or non-TCM users based on their use of TCM.ResultsIn Taiwan, 8086 (62.4%) children with cancer sought TCM treatment at some point. Children in older age groups, including school-a

Совпадение в полном тексте источника
… All the pediatric cancer patients were diagnosed as having catastrophic diseases by hematologists or oncologists. Therefore, they all received diagnoses and visited Western medical doctors whether they were TCM users or non–TCM users. … Third, pediatric cancer patients with CICs were confirmed by pathology, image studies, a series of laboratory surveys, and careful review by hematologists and oncologists commissioned by the NHI Administration. …

Материалы Международного общества по картированию раковых заболеваний (ИСИС) 18th Ежегодный учебный курс: Ментон, Франция. 7-9 октябрь 2018

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Oncologist 2008, 13 Suppl 2:8-13. PMID 18434632 Hodi, F. S. et al . Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363 , 711–723. Topalian, S. L. et al . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. … In 2017, paediatric radiologists, oncologists, and surgeons from Europe, Japan, and the United States met to update the classification system via a consensus session. …

Use of Herbal Medicine Is Associated With Late-Stage Presentation in Tanzanian Patients With Cancer: A Survey to Assess the Utilization of and Reasons for the Use of Herbal Medicine.

PurposeIn Tanzania, patients with cancer present late with advanced stages. Among other reasons, the use of herbal medicine (HM) might contribute to delay in diagnosis and treatment. This study aims to understand the utilization of HM and the reasons for its' use.MethodsA semistructured 30-item questionnaire with closed- and open-ended questions was applied to a cohort of patients with cancer at Kilimanjaro Christian Medical Centre. Content analysis was performed for answers to open-ended questions.ResultsThree hundred two patients were interviewed, 50.9% males and 49.1% females. The mean age

Совпадение в полном тексте источника
… This is also known as a common motivation for patients with cancer in different settings. 24 - 26 The majority of the interviewed patients would not talk to their oncologists about the concurrent use of HM. … This finding must alert Tanzanian oncologists (and globally as other studies have shown) to thoroughly obtain the history of patients including the pointed question about HM use and the reasons behind it. …

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting.

BackgroundConcern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We hypothesized that the clinical trials that do not report race are likely to suffer from a higher degree of age disparity.MethodsFood and Drug Administration (FDA) drug approvals from July 2007 to June 2019 were reviewed to identify oncology approvals, and trials with age details were selected. The outcomes studied were the weighted mean difference in age between the

Predicting Pathologic Bone Lesions Using Scout Computed Tomography (CT) Imaging.

The purpose of this study is to evaluate the benefit of reviewing scout CT images, obtained for routine oncologic surveillance, for the early identification of pathologic bony lesions. A retrospective review was conducted on patients who previously underwent surgical treatment by two orthopedic oncology surgeons at a tertiary care institution from 2009-2019 for pathologic lesions or fractures of the humerus or femur. Radiographic records were reviewed to identify patients in this cohort who had available scout views from CT imaging prior to official diagnosis of the bony lesion or fracture. CT

Совпадение в полном тексте источника
… Medical oncologists who are reviewing surveillance imaging also may not be specifically trained in radiographic review to identify lesions and/or impending fractures, and orthopedic oncologists are generally involved after diagnosis. … Finally, while our patient population was limited to those who were treated by an orthopedic oncologist, there are many patients with pathologic bony lesions who are treated with radiation therapy alone and are never seen by an orthopedist. …

Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.

Bone metastases are a major concern in cancer management since they significantly contribute to morbidity and mortality. Metastatic lesions, commonly arising from breast, prostate, lung, and kidney cancers, affect approximately 25% of cancer patients, leading to severe complications such as pain, fractures, and neurological deficits. This narrative review explores contemporary approaches to bone metastases, emphasizing a multidisciplinary strategy and the evolving concept of oligometastatic disease. Oligometastases, defined by limited metastatic spread (1-5 lesions), offer a potential window f

Совпадение в полном тексте источника
… Consequently, multidisciplinarity and collaboration between surgeons, radiotherapists, and oncologists is pivotal. 3.5. … For example, while surgical oncologists may focus on resecting isolated metastases, radiation oncologists might advocate for SBRT, and medical oncologists may favor systemic therapies like chemotherapy, targeted treatments, or immunotherapy. …